Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

Background The purpose of this study was to identify clinical and pathological parameters to improve prediction of disease-free survival (DFS) and overall survival (OS) in patients treated with neoadjuvant chemoradiotherapy for rectal cancer. Methods Between July 1995 and May 2007, 148 patients with...

Full description

Saved in:
Bibliographic Details
Published in:International journal of colorectal disease 2009-07, Vol.24 (7), p.741-748
Main Authors: Moreno García, V, Cejas, P, Blanco Codesido, M, Feliu Batlle, J, de Castro Carpeño, J, Belda-Iniesta, C, Barriuso, J, Sánchez, J. J, Larrauri, J, González-Barón, M, Casado, E
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoembryonic Antigen - blood
Disease-Free Survival
Female
Gastroenterology
Gastroenterology. Liver. Pancreas. Abdomen
Hepatology
Humans
Internal Medicine
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neoadjuvant Therapy
Original Article
Proctology
Prognosis
Rectal Neoplasms - blood
Rectal Neoplasms - diagnosis
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
Recurrence
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Surgery
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The purpose of this study was to identify clinical and pathological parameters to improve prediction of disease-free survival (DFS) and overall survival (OS) in patients treated with neoadjuvant chemoradiotherapy for rectal cancer. Methods Between July 1995 and May 2007, 148 patients with primary rectal adenocarcinoma received neoadjuvant chemoradiotherapy followed by mesorectal excision. Preoperative treatment included various protocols, UFT and leucovorin (28%) and oxaliplatin-based chemotherapy (72%). Clinical and pathological variables were evaluated in relation to patient outcomes. Results Thirteen percent of patients achieved a complete pathologic response. No response or minimal response as defined by Dworak (Tumor Regression Grade 0/1) was observed in 30 patients (20%). At a median follow-up of 37 months, the 3-year DFS and OS were 64% and 83%, respectively. Pre-treatment serum carcinoembryonic antigen (CEA) level
ISSN:0179-1958
1432-1262
DOI:10.1007/s00384-009-0682-6